You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞虹醫藥(688176.SH):APL-1202目前正在重點開展三項臨牀試驗
格隆匯 01-31 07:43

格隆匯1月31日丨亞虹醫藥(688176.SH)近日在接待機構投資者調研時表示,APL-1202目前正在重點開展三項臨牀試驗,APL-1202口服聯合替雷利珠單抗作為肌層浸潤性膀胱癌(MIBC)新輔助治療的Ⅰ/Ⅱ期臨牀試驗於2023年9月完成Ⅱ期臨牀試驗期中分析並取得積極結果,且該項臨牀試驗期中分析結果將在2024年美國臨牀腫瘤學會泌尿生殖系腫瘤分會(ASCO-GU)年會上披露;APL-1202與化療灌注聯合使用治療化療灌注復發的中高危NMIBC的關鍵性臨牀試驗,目前公司在積極準備該項臨牀試驗的數據清理等相關工作;APL-1202單藥治療未經治療的中危NMIBC Ⅲ期臨牀試驗在積極推進該臨牀受試者的入組招募。關於後續臨牀結果,公司將根據相關規定及時履行信息披露義務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account